Volume 73, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


As infants lose maternally derived antibody, they experience a period when antibody levels are insufficient to protect against measles yet may interfere with immunization. In Kangaba Mali, sera were collected from 89 2–8-month-old infants and 32 9–10-month-old infants without a history of measles or vaccination; post-vaccination sera were collected from 24 of the 9–10-month-old infants 3–5 weeks after receiving measles vaccine. Measles antibody was measured by plaque reduction neutralization (PRN) and enzyme linked immunosorbent assay. At two months of age, 30% had protective PRN titers; among six-month-old infants, none had protective titers. Prior to vaccination, 16% of 9–10-month-old infants exhibited protective titers; all demonstrated protective titers post-vaccination. The early onset of the window of vulnerability in Kangaba infants likely reflects the changing ecology of measles in Africa. Ways to protect these vulnerable infants against measles must be devised.


Article metrics loading...

Loading full text...

Full text loading...



  1. 2003. Measles mortality reduction in West Africa, 1996–2002. Wkly Epidemiol Rec 78 : 390–392.
  2. Taylor WR, Mambu RK, Ma-Disu M, Weinman JM, 1988. Measles control efforts in urban Africa complicated by high incidence of measles in the first year of life. Am J Epidemiol 127 : 788–794.
  3. Duke T, Mgone CS, 2003. Measles: not just another viral exanthem. Lancet 361 : 763–773.
  4. Gans HA, Yasukawa LL, Alderson A, Rinki M, DeHovitz R, Beeler J, Audet S, Maldonado Y, Arvin AM, 2004. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 190 : 83–90.
  5. Papania M, Baughman AL, Lee S, Cheek JE, Atkinson W, Redd SC, Spitalny K, Finelli L, Markowitz L, 1999. Increased susceptibility to measles in infants in the United States. Pediatrics 104 : e59.
  6. Markowitz LE, Albrecht P, Rhodes P, Demonteverde R, Swint E, Maes EF, Powell C, Patriarca PA, 1996. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. Pediatrics 97 : 53–58.
  7. Maldonado YA, Lawrence EC, DeHovitz R, Hartzell H, Albrecht P, 1995. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics 96 : 447–450.
  8. Okoko BJ, Wesuperuma LH, Ota MO, Banya WA, Pinder M, Gomez FS, Osinusi K, Hart AC, 2001. Influence of placental malaria infection and maternal hypergammaglobulinaemia on maternofoetal transfer of measles and tetanus antibodies in a rural west African population. J Health Popul Nutr 19 : 59–65.
  9. Black FL, Berman LL, Borgono JM, Capper RA, Carvalho AA, Collins C, Glover O, Hijazi Z, Jacobson DL, Lee YL, 1986. Geographic variation in infant loss of maternal measles antibody and in prevalence of rubella antibody. Am J Epidemiol 124 : 442–452.
  10. Eghafona NO, Ahmad AA, Odama LE, Onuora C, Gosham LT, Emejuaiwe SO, Woghiren EI, 1987. The levels of measles antibodies in Nigerian children aged 0–12 months and its relationship with maternal parity. Epidemiol Infect 99 : 547–550.
  11. Hartter HK, Oyedele OI, Dietz K, Kreis S, Hoffman JP, Muller CP, 2000. Placental transfer and decay of maternally acquired antimeasles antibodies in Nigerian children. Pediatr Infect Dis J 19 : 635–641.
  12. Okoko JB, Wesumperuma HL, Hart CA, 2001. The influence of prematurity and low birthweight on transplacental antibody transfer in a rural west African population. Trop Med Int Health 6 : 529–534.
  13. Caceres VM, Strebel PM, Sutter RW, 2000. Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin Infect Dis 31 : 110–119.
  14. Raote GJ, Bhave SY, 1992. Clinical profile of measles–a prospective study of 150 hospital based children. Indian Pediatr 29 : 45–48.
  15. Garenne M, Aaby P, 1990. Pattern of exposure and measles mortality in Senegal. J Infect Dis 161 : 1088–1094.
  16. Aaby P, Bukh J, Hoff G, Leerhoy J, Lisse IM, Mordhorst CH, Pedersen IR, 1986. High measles mortality in infancy related to intensity of exposure. J Pediatr 109 : 40–44.
  17. Hull HF, Williams PJ, Oldfield F, 1983. Measles mortality and vaccine efficacy in rural west Africa. Lancet 1 : 972–975.
  18. Job JS, Halsey NA, Boulos R, Holt E, Farrell D, Albrecht P, Brutus JR, Adrien M, Andre J, Chan E, 1991. Successful immunization of infants at 6 months of age with high dose Edmonston-Zagreb measles vaccine. Cite Soleil/JHU Project Team. Pediatr Infect Dis J 10 : 303–311.
  19. Halsey NA, 1993. Increased mortality after high titer measles vaccines: too much of a good thing. Pediatr Infect Dis J 12 : 462–465.
  20. Aaby P, Knudsen K, Whittle HC, Lisse IM, Thaarup J, Poulsen A, 2003. Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate. J Pediatr 122 : 904–908.
  21. Kertesz DA, Toure K, Berthe A, Konate Y, Bougoudogo F, 2003. Evaluation of urban measles mass campaigns for children aged 9–59 months in Mali. J Infect Dis 187 (Suppl 1): S69–S73.
  22. Pasetti MF, Barry EM, Losonsky G, Singh M, Medina-Moreno SM, Polo JM, Ulmer J, Robinson H, Sztein MB, Levine MM, 2003. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. J Virol 77 : 5209–5217.
  23. Polack FP, Hoffman SJ, Moss WJ, Griffin DE, 2003. Differential effects of priming with DNA vaccines encoding the hemagglutinin and/or fusion proteins on cytokine responses after measles virus challenge. J Infect Dis 187 : 1794–1800.
  24. Dabis F, Waldman RJ, Mann GF, Commenges D, Madzou G, Jones TS, 1989. Loss of maternal measles antibody during infancy in an African city. Int J Epidemiol 18 : 264–268.
  25. de Francisco A, Hall AJ, Unicomb L, Chakraborty J, Yunus M, Sack RB, 1998. Maternal measles antibody decay in rural Bangladeshi infants–implications for vaccination schedules. Vaccine 16 : 564–568.
  26. Albrecht P, Herrmann K, Burns GR, 1981. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 3 : 251–260.
  27. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA, 1990. Measles antibody: reevaluation of protective titers. J Infect Dis 162 : 1036–1042.
  28. Kiepiela P, Coovadia HM, Loening WE, Coward P, Abdool Karim SS, 1991. Loss of maternal measles antibody in black South African infants in the first year of life–implications for age of vaccination. S Afr Med J 79 : 145–148.
  29. Cutts FT, 1993. Module 7: Measles, The Immunological Basis for Immunization Series. Geneva: World Health Organization.
  30. Forsey T, Heath AB, Minor PD, 1991. The 1st International Standard for anti-measles serum. Biologicals 19 : 237–241.
  31. Embree JE, Datta P, Stackiw W, Sekla L, Braddick M, Kreiss JK, Pamba H, Wamola I, Ndinya-Achola JO, Law BJ, 1992. Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers. J Infect Dis 165 : 262–267.
  32. Lyke KE, Diallo DA, Dicko A, Kone A, Coulibaly D, Guindo A, Cissoko Y, Sangare L, Coulibaly S, Dakouo B, Taylor TE, Doumbo OK, Plowe CV, 2003. Association of intraleukocytic Plasmodium falciparum malaria pigment with disease severity, clinical manifestations, and prognosis in severe malaria. Am J Trop Med Hyg 69 : 253–259.
  33. Bouvier P, Rougemont A, Breslow N, Doumbo O, Delley V, Dicko A, Diakite M, Mauris A, Robert CF, 1997. Seasonality and malaria in a west African village: does high parasite density predict fever incidence? Am J Epidemiol 145 : 850–857.
  34. Putz MM, Bouche FB, de Swart RL, Muller CP, 2003. Experimental vaccines against measles in a world of changing epidemiology. Int J Parasitol 33 : 525–545.
  35. Garly ML, Aaby P, 2003. The challenge of improving the efficacy of measles vaccine. Acta Trop 85 : 1–17.
  36. Ohsaki M, Tsutsumi H, Takeuchi R, Kuniya Y, Chiba S, 1999. Reduced passive measles immunity in infants of mothers who have not been exposed to measles outbreaks. Scand J Infect Dis 31 : 17–19.
  37. Bennett J, Whittle H, Samb B, Cisse B, Simondon F, Aaby P, 1999. Seroconversions in unvaccinated infants: further evidence for subclinical measles from vaccine trials in Niakhar, Senegal. Int J Epidemiol 28 : 147–151.
  38. Whittle HC, Aaby P, Samb B, Jensen H, Bennett J, Simondon F, 1999. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in west Africa. Lancet 353 : 98–102.
  39. Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J, Audet S, Maldonado Y, Arvin AM, 2001. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 184 : 817–826.
  40. Gans H, DeHovitz R, Forghani B, Beeler J, Maldonado Y, Arvin AM, 2003. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 21 : 3398–3405.
  41. Ratnam S, Gadag V, West R, Burris J, Oates E, Stead F, Bouilianne N, 1995. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol 33 : 811–815.
  42. Goncalves G, Cutts FT, Forsey T, Andrade HR, 1999. Comparison of a commercial enzyme immunoassay with plaque reduction neutralization for maternal and infant antibody measurement. Rev Inst Med Trop Sao Paolo 41 : 21–26.

Data & Media loading...

  • Received : 08 Oct 2004
  • Accepted : 22 Dec 2004

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error